HLX22 plus HLX87 as first-line treatment for HER2-positive recurrent or metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The program includes two open-label, randomized, parallel-controlled stages: a Phase II portion focused on objective response rate (ORR) and progression-free survival (PFS), followed by a Phase III portion with PFS as the primary endpoint. Patients with centrally confirmed HER2-positive recurrent or metastatic breast cancer who have not received prior chemotherapy or HER2-targeted therapy for advanced disease are eligible. Treatment arms include HLX22+HLX87 and comparator regimens such as HLX87+pertuzumab, T-DXd+pertuzumab, and THP, with central imaging review by RECIST v1.1. The trial is sponsored by Shanghai Henlius Biotech and conducted at the Cancer Hospital, Chinese Academy of Medical Sciences in Beijing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Have a full understanding of the study content, and sign the informed consent form (ICF); 2. Aged ≥ 18 years at the time of signing the ICF, male or female; 3. Histopathologically confirmed breast cancer that meets the following criteria:

  1. Advanced or metastatic breast cancer.
  2. HER2-positive as determined by the central laboratory, defined as IHC 3+, or IHC 2+ and ISH+.
  3. Positive or negative for hormone receptor HR (including estrogen receptor \[ER\] and progesterone receptor \[PgR\]) as determined by the central laboratory 4. No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer (1 line of endocrine therapy is allowed).

  5\. At least one measurable lesion as assessed by central imaging according to RECIST v1.1.

  7\. Eastern Cooperative Oncology Group performance status score within 7 days prior to the first dose of study drugs: 0-1.

  8\. Life expectancy ≥ 12 weeks. 9. Adequate organ functions

Exclusion Criteria:

* 1\. History of a second malignancy within 3 years prior to signing the ICF. 2. Previous use of doxorubicin with a concentration of \> 360 mg/m2 (or equivalent).

  3\. Prior treatment with ADCs including exatecan derivatives that contain topoisomerase I inhibitors.

  4\. Uncontrolled or significant cardiovascular diseases 5. Cerebrovascular accidents within 6 months prior to the first dose of study drugs.

  6\. ILD/pneumonitis, or suspected ILD/pneumonitis or clinically significant lung-specific intercurrent illness .

  7\. Active infection . 8. Presence of spinal cord compression or clinically symptomatic central nervous system metastases.

  9\. Residual toxicity from previous anti-tumor therapy that has not resolved to Grade ≤ 1 as per NCI-CTCAE V6.0 or baseline level (except for alopecia).

  10\. Presence of active tuberculosis. 11. Have received treatment with live attenuated vaccines within 30 days prior to the first dose of study drugs.

  12\. Known history of severe allergic reaction to macromolecular protein preparations, hypersensitivity to the ingredient of the investigational products, or severe hypersensitivity to any excipient of the study drugs.

  13\. Known history of abuse of psychotropic drugs or drug addiction. 14. Pregnant or lactating women.

Where it's running

• Cancer Hospital, Chinese Academy of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Fei Ma, Dr — Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
• Study coordinator: Maoqing Fu, Dr
• Email: Maoqing_fu@henlius.com
• Phone: 021-33395800

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Oral paclitaxel with anti-HER2 therapy in HER2-positive breast cancer before surgery

  This trial tests a paclitaxel oral solution given with trastuzumab and pertuzumab to see if a safe dose can be found for women with HER2-positive breast cancer before they have surgery.

  Recruiting Phase 1/2 The Affiliated Hospital Of Guizhou Medical University · Guiyang, Guizhou · NCT07739511

• Olaparib with Trastuzumab and Pertuzumab before surgery for older women with HER2-positive breast cancer

  This trial tests whether adding olaparib to standard HER2-targeted therapy can help older women with newly diagnosed, operable HER2-positive breast cancer before surgery.

  Recruiting Phase 4 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07695259

• Pyrotinib-based regimens for advanced HER2-positive breast cancer: real-world sequential therapy after progression

  This real-world study tests whether giving disitamab vedotin after pyrotinib-based treatment helps people with advanced HER2-positive breast cancer.

  Recruiting Phase 4 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07600164

• Pre-surgery trastuzumab deruxtecan (SHR-A1811) plus pertuzumab for HER2-positive breast cancer

  This trial tests giving trastuzumab deruxtecan (SHR-A1811) with pertuzumab before surgery to see if it helps women with stage II–III HER2-positive breast cancer achieve a complete response.

  Recruiting Phase 2 Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07393425

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.